Document 0673
 DOCN  M9650673
 TI    Glycosylation inhibitors in biology and medicine.
 DT    9605
 AU    Jacob GS; GD Searle, St Louis, USA.
 SO    Curr Opin Struct Biol. 1995 Oct;5(5):605-11. Unique Identifier :
       AIDSLINE MED/96127424
 AB    Glycosidase inhibitors are moving increasingly out of the laboratory and
       into the clinic as potential agents for the treatment of diseases
       including diabetes, AIDS and cancer. These compounds, originally
       isolated from natural sources and utilized for unraveling the
       glycosylation pathways involved in post-translational modification of
       glycoproteins, have multiple effects that are only now being fully
       appreciated. In addition to their ability to inhibit processing
       exoglycosidases, lysosomal glycosidases and the intestinal
       disaccharidases involved in carbohydrate digestion, these compounds
       appear to have additional activities, including immunomodulatory
       properties and inhibition of glycolipid synthesis, which continue to
       expand their range of potential uses.
 DE    Adjuvants, Immunologic/PHARMACOLOGY  Animal  Antineoplastic Agents,
       Phytogenic/PHARMACOLOGY  Antiviral Agents/PHARMACOLOGY  Diabetes
       Mellitus/DRUG THERAPY  Enzyme Inhibitors/CHEMISTRY/*PHARMACOLOGY
       Glycoproteins/CHEMISTRY/METABOLISM  Glycoside Hydrolases/*ANTAGONISTS &
       INHIB  Glycosylation/DRUG EFFECTS  Human  HIV/DRUG EFFECTS  Molecular
       Structure  Polysaccharides/METABOLISM  Protein Processing,
       Post-Translational  Swainsonine/PHARMACOLOGY  JOURNAL ARTICLE  REVIEW
       REVIEW, TUTORIAL

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).